# Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer

> **NCT00979641** · PHASE2 · TERMINATED · sponsor: **Tampere University Hospital** · enrollment: 65 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00979641
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 65 (ACTUAL)
- **Why stopped:** Participants are no longer being examined. The results are published 2016 Anticancer Research 36: 6431-6438
- **Last updated:** 2019-03-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979641, "Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00979641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*